Gloria Adams

I learned in about 2002, when I was applying for a wage loss insurance, that somewhere along in my years, I had contracted this hep C. What a shock!!! I definitely had not been on anyone’s list of risky behaviour and had not even felt sick enough to see a Dr. in over 2 years.

Then, in 2004 when I learned that my liver was already in Stage 3 – full bridging fibrosis, I began the treatment (pegalated interferon and ribavirin) in September and completed that in August 2005. However, I was to experience another major shock at that period. Although I had faithfully done 48 miserable weeks of the treatment and had shown response in the first 3 months, it ended with the fact, that I was a Non-Responder. I felt devastated at the time and as much as I tried, could not find a whole lot of support or even research about what happens when a person has not responded. The whole research was definitely still too new regarding hep C and so I realized that no one could actually predict what could happen in my case.

Then, in January 2009, I received a surprising phone call from a hep C nurse that works locally, in a society that helps and supports persons with hep C. She asked if I would be interested in joining a Clinical Trial being run out of Vancouver and that I had very little time to decide. Boy, was she right! In actual fact, I only had 4 hours and had to call Vancouver and tell them YES. However, I can never say Thank You enough to this nurse for remembering me and suggesting my name in the first place. Quickly, I learned that my liver had indeed progressed to early stage cirrhosis. Thus began another journey through another 48 weeks of medication, including, the as of yet not released extra pills, along with the interferon/riba. I am very very happy to say, that I learned in October 2009 that my body had reached HCV-RNA negative and that has not changed since. Hopefully, in July 2010, I will be declared as having a Sustained Viral Response.

But, troubles were not over with my liver just yet. When I had been off the treatment a scant two weeks, my Gastroenterologist called to confirm that I did indeed have two cancer tumours on my liver. So there were days when I felt like I had been kicked in the stomach and other days that I was extremely grateful that I was attending a clinic in Vancouver and that the tumours were found quickly, only because I was on the Clinical Trial. As of today, I am still recovering after a liver resection was performed on me on April 7th.

As of today and for the rest of my foreseeable future, I intend to live only in the positive.

I would like to be available to help ANY other person that is facing this horrible dragon!!! I believe that we all must come together as one voice, in order to raise awareness and education others about both diseases (hep B and hep C) and the literal hundreds of thousands lives they affect every single day! I really do believe that both kinds of hepatitis is an epidemic around the world and not nearly enough has been done by various governments or health organizations to allow this news to be made public. The silence must end NOW.

Share your story now

For people living with a hepatitis condition, it really helps to know they’re not alone. That’s why we’re inviting people to share their stories.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close